Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease: Drugs Targeting Obesity and Type 2 Diabetes.

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly nonalcoholic fatty liver disease, is increasingly prevalent and closely linked to obesity and type 2 diabetes (T2D). These metabolic conditions not only represent drivers of disease progression, but also as therapeutic targets for modifying the disease course. This study reviews the pathophysiological contributions of obesity and T2D to MASLD and evaluates pharmacologic strategies aimed at these drivers. Incretin-based therapies, especially GLP-1 receptor agonists and co-agonists have emerged as leading agents in promoting weight loss, reducing cardiovascular and renal outcomes in T2D and obesity.